



Bydureon[®] (exenatide) – Product discontinuation

- The [FDA announced](#) the permanent discontinuation of [AstraZeneca's Bydureon \(exenatide\)](#) single-dose tray (SDT) formulation.
 - The discontinuation is not due to any safety, efficacy, or quality issues.
 - Bydureon SDT will be available until September 30, 2018.
 - Bydureon Pen and [Bydureon[®] BCise[™]](#) will continue to be available.
- Bydureon Pen contains the same formulation and dose as Bydureon SDT. Bydureon BCise contains the same dose of exenatide as Bydureon Pen and Bydureon SDT; however, it uses an oil based diluent.
- Bydureon is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
 - Bydureon is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of the rat thyroid C-cell tumor findings to humans.
 - Bydureon is not a substitute for insulin. Bydureon is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.
 - The concurrent use of Bydureon with prandial insulin has not been established.
 - Bydureon is an extended-release formulation of exenatide. Bydureon should not be used with other products containing the active ingredient exenatide.
 - Bydureon has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- When switching patients from Bydureon SDT to either Bydureon Pen or Bydureon BCise, Bydureon SDT should be discontinued prior to initiation of Bydureon Pen or Bydureon BCise.
- Patients changing from Bydureon SDT to Bydureon Pen or Bydureon BCise may do so at the next regularly scheduled dose.
- Bydureon carries a boxed warning for risk of thyroid C-cell tumors.
- For additional questions, contact AstraZeneca at **1-800-236-9933**.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.